Daniel C Beachler1, Cynthia de Luise2, Aziza Jamal-Allial3, Ruihua Yin4, Devon H Taylor3, Ayako Suzuki5, James H Lewis6, James W Freston7, Stephan Lanes3. 1. HealthCore, Inc., 123 Justison Street, Suite 200, Wilmington, DE, 19801, USA. dbeachler@healthcore.com. 2. Pfizer Inc., New York, NY, USA. 3. HealthCore, Inc., 123 Justison Street, Suite 200, Wilmington, DE, 19801, USA. 4. Anthem, Inc., Andover, MA, USA. 5. Duke University School of Medicine, Durham, NC, USA. 6. Georgetown University School of Medicine, Washington, DC, USA. 7. University of Connecticut Health Center, Farmington, CT, USA.
Abstract
BACKGROUND: There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. METHODS: We conducted a cohort study of breast cancer patients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrated Research Database (HIRD), a longitudinal claims database of commercial health plan members in the United States. The historical comparator cohort comprised patients initiating fulvestrant monotherapy from January 2011 to January 2015. Propensity score matching and Cox regression were used to estimate hazard ratios for various safety events. For acute liver injury (ALI), additional analyses and medical record validation were conducted. RESULTS: There were 2445 patients who initiated palbociclib including 566 new users of palbociclib-fulvestrant, and 2316 historical new users of fulvestrant monotherapy. Compared to these historical new users of fulvestrant monotherapy, new users of palbociclib-fulvestrant had a greater than 2-fold elevated risk for neutropenia, leukopenia, thrombocytopenia, stomatitis and mucositis, and ALI. Incidence of anemia and QT prolongation were more weakly associated, and incidences of serious infections and pulmonary embolism were similar between groups after propensity score matching. After adjustment for additional ALI risk factors, the elevated risk of ALI in new users of palbociclib-fulvestrant persisted (e.g. primary ALI algorithm hazard ratio (HR) = 3.0, 95% confidence interval (CI) = 1.1-8.4). CONCLUSIONS: This real-world study found increased risks of several adverse events identified in clinical trials, including neutropenia, leukopenia, and thrombocytopenia, but no increased risk of serious infections or pulmonary embolism when comparing new users of palbociclib-fulvestrant to fulvestrant monotherapy. We observed an increased risk of ALI, extending clinical trial findings of significant imbalances in grade 3/4 elevations of alanine aminotransferase (ALT).
BACKGROUND: There is limited real-world safety information on palbociclib for treatment of advanced stage HR+/HER2- breast cancer. METHODS: We conducted a cohort study of breast cancerpatients initiating palbociclib and fulvestrant from February 2015 to September 2017 using the HealthCore Integrated Research Database (HIRD), a longitudinal claims database of commercial health plan members in the United States. The historical comparator cohort comprised patients initiating fulvestrant monotherapy from January 2011 to January 2015. Propensity score matching and Cox regression were used to estimate hazard ratios for various safety events. For acute liver injury (ALI), additional analyses and medical record validation were conducted. RESULTS: There were 2445 patients who initiated palbociclib including 566 new users of palbociclib-fulvestrant, and 2316 historical new users of fulvestrant monotherapy. Compared to these historical new users of fulvestrant monotherapy, new users of palbociclib-fulvestrant had a greater than 2-fold elevated risk for neutropenia, leukopenia, thrombocytopenia, stomatitis and mucositis, and ALI. Incidence of anemia and QT prolongation were more weakly associated, and incidences of serious infections and pulmonary embolism were similar between groups after propensity score matching. After adjustment for additional ALI risk factors, the elevated risk of ALI in new users of palbociclib-fulvestrant persisted (e.g. primary ALI algorithm hazard ratio (HR) = 3.0, 95% confidence interval (CI) = 1.1-8.4). CONCLUSIONS: This real-world study found increased risks of several adverse events identified in clinical trials, including neutropenia, leukopenia, and thrombocytopenia, but no increased risk of serious infections or pulmonary embolism when comparing new users of palbociclib-fulvestrant to fulvestrant monotherapy. We observed an increased risk of ALI, extending clinical trial findings of significant imbalances in grade 3/4 elevations of alanine aminotransferase (ALT).
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: Vincent Lo Re; Kevin Haynes; David Goldberg; Kimberly A Forde; Dena M Carbonari; Kimberly B F Leidl; Sean Hennessy; K Rajender Reddy; Pamala A Pawloski; Gregory W Daniel; T Craig Cheetham; Aarthi Iyer; Kara O Coughlin; Sengwee Toh; Denise M Boudreau; Nandini Selvam; William O Cooper; Mano S Selvan; Jeffrey J VanWormer; Mark I Avigan; Monika Houstoun; Gwen L Zornberg; Judith A Racoosin; Azadeh Shoaibi Journal: Pharmacoepidemiol Drug Saf Date: 2013-06-25 Impact factor: 2.890
Authors: Daniel C Beachler; Cynthia de Luise; Ruihua Yin; Kelsey Gangemi; Philip T Cochetti; Stephan Lanes Journal: Pharmacoepidemiol Drug Saf Date: 2018-11-09 Impact factor: 2.890
Authors: Raul J Andrade; Naga Chalasani; Einar S Björnsson; Ayako Suzuki; Gerd A Kullak-Ublick; Paul B Watkins; Harshad Devarbhavi; Michael Merz; M Isabel Lucena; Neil Kaplowitz; Guruprasad P Aithal Journal: Nat Rev Dis Primers Date: 2019-08-22 Impact factor: 52.329
Authors: K Arnold Chan; Alison Truman; Jerry H Gurwitz; Judith S Hurley; Brian Martinson; Richard Platt; James E Everhart; Richard H Moseley; Norah Terrault; Lynn Ackerson; Joe V Selby Journal: Arch Intern Med Date: 2003-03-24
Authors: Richard S Finn; Miguel Martin; Hope S Rugo; Stephen Jones; Seock-Ah Im; Karen Gelmon; Nadia Harbeck; Oleg N Lipatov; Janice M Walshe; Stacy Moulder; Eric Gauthier; Dongrui R Lu; Sophia Randolph; Véronique Diéras; Dennis J Slamon Journal: N Engl J Med Date: 2016-11-17 Impact factor: 91.245
Authors: Véronique Diéras; Hope S Rugo; Patrick Schnell; Karen Gelmon; Massimo Cristofanilli; Sherene Loi; Marco Colleoni; Dongrui R Lu; Ave Mori; Eric Gauthier; Cynthia Huang Bartlett; Dennis J Slamon; Nicholas C Turner; Richard S Finn Journal: J Natl Cancer Inst Date: 2019-04-01 Impact factor: 13.506